Location · Fairhope, AL
Clinical trials in Fairhope, AL
19 recruiting studies have a site in Fairhope, and 0 of them accept healthy volunteers.
19 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Fairhope, AL + 151 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Regeneron Pharmaceuticals
- Location
- Fairhope, AL + 41 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Alnylam Pharmaceuticals
- Location
- Fairhope, AL + 213 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Novartis Pharmaceuticals
- Location
- Fairhope, AL + 8 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Fairhope, AL + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Fairhope, AL + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Fairhope, AL + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Fairhope, AL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
AstraZeneca
- Location
- Fairhope, AL + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- Fairhope, AL + 104 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
AstraZeneca
- Location
- Fairhope, AL + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Fairhope, AL + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Fairhope, AL + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and…
Novo Nordisk A/S
- Location
- Fairhope, AL + 55 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Cytokinetics
- Location
- Fairhope, AL + 23 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
- Location
- Fairhope, AL + 206 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Fairhope, AL + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk A/S
- Location
- Fairhope, AL + 129 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Fairhope, AL + 112 other US sites
- Eligibility basics
- Ages 45+